[The anti-tubercular drugs in the treatment of psoriasis].
Psoriasis - systemic disease, including complex of interdependent pathogenetic links, which attach great importance to immunological disorders. According to recent years, the basis of the pathogenesis of psoriasis is the migration of T-lymphocytes from the blood into the skin, where they activate and start a cascade release of proinflammatory cytokines. The aim of the study was the assessment of therapeutic effectiveness of the phased application of Rifampicin and electropulse therapy in the treatment of patients with psoriasis. Under observation were 25 patients with vulgar psoriasis (13 women and 12 men aged from 18 to 65 years, with duration of illness from 1 month to 25 years). Rifampicin was prescribed to a daily dose of 600 mg for 60 days. Topical therapy was limited by the use of emollients. During the sessions of electropulse therapy the apparatus of elctronarcosis has been used. The state of the patients assessed 2 times a month. The effectiveness of treatment in patients receiving Rifampicin was the same regardless of the presence or absence of concomitant bacterial infection, which suggests that the positive therapeutic results of rifampicin is related not to its antibacterial, but to immunomodulatory effects. As a conclusion we can say that, the application of electropulse therapy and Rifampicin phase-treatment in patients with psoriasis reduces the period of the normalization of clinical indices for 7 days, as well as 2,5 times reduces the frequency of relapses in the year.
Tsiskarishvili
N V
NV
Tsiskarishvili
N I
NI
D000293:Adolescent; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004599:Electric Stimulation Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012293:Rifampin / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D000995:Antitubercular Agents; D012293:Rifampin